title: Long-Term Burden and Respiratory Effects of Respiratory Syncytial Virus Hospitalization in Preterm Infants-The SPRING Study.
abstract: The health status of premature infants born 321-350 weeks' gestational age (wGA) hospitalized for RSV infection in the first year of life (cases; n = 125) was compared to that of premature infants not hospitalized for RSV (controls; n = 362) through 6 years. The primary endpoints were the percentage of children with wheezing between 2-6 years and lung function at 6 years of age. Secondary endpoints included quality of life, healthcare resource use, and allergic sensitization. A significantly higher proportion of cases than controls experienced recurrent wheezing through 6 years of age (46.7% vs. 27.4%; p = 0.001). The vast majority of lung function tests appeared normal at 6 years of age in both cohorts. In children with pulmonary function in the lower limit of normality (FEV1 Z-score [-2; -1]), wheezing was increased, particularly for cases vs. controls (72.7% vs. 18.9%, p = 0.002). Multivariate analysis revealed the most important factor for wheezing was RSV hospitalization. Quality of life on the respiratory subscale of the TAPQOL was significantly lower (p = 0.001) and healthcare resource utilization was significantly higher (p<0.001) in cases than controls. This study confirms RSV disease is associated with wheezing in 32-35 wGA infants through 6 years of age.
authors.affiliation: Neonatology Service, Hospital Clinic, Institut d'Investigacions Biomediques August Pi Suñer (IDIBAPS), Barcelona, Spain.
authors.forename: Xavier
authors.initials: X
authors.lastname: Carbonell-Estrany
authors.affiliation: Division of Pediatric Respiratory Medicine, Hospital Universitario Donostia-Instituto Biodonostia, San Sebastián, Spain; Biomedical Research Centre Network for Respiratory Diseases (CIBERES), San Sebastián, Spain; Department of Pediatrics, University of the Basque Country (UPV/EHU), San Sebastián, Spain.
authors.forename: Eduardo G
authors.initials: EG
authors.lastname: Pérez-Yarza
authors.affiliation: Neonatology Unit, Hospital Universitario La Paz, Madrid, Spain.
authors.forename: Laura Sanchez
authors.initials: LS
authors.lastname: García
authors.affiliation: Neonatology Service, Hospital Universitario Reina Sofía, Córdoba, Spain.
authors.forename: Juana M
authors.initials: JM
authors.lastname: Guzmán Cabañas
authors.affiliation: Health Outcomes Research Department, 3D Health Research, Barcelona, Spain.
authors.forename: Elena Villarrubia
authors.initials: EV
authors.lastname: Bòria
authors.affiliation: Neonatology Division, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario "Gregorio Marañón", Madrid, Spain.
authors.forename: Belén Bernardo
authors.initials: BB
authors.lastname: Atienza
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D005260:Female; D005865:Gestational Age; D006760:Hospitalization / Q000706:statistics & numerical data*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000188:drug therapy / Q000503:physiopathology* / Q000821:virology; D008297:Male; D000069455:Palivizumab / Q000627:therapeutic use; D010342:Patient Acceptance of Health Care / Q000706:statistics & numerical data; D011446:Prospective Studies; D011788:Quality of Life; D012129:Respiratory Function Tests; D012135:Respiratory Sounds / Q000209:etiology / Q000503:physiopathology*; D018357:Respiratory Syncytial Virus Infections / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology* / Q000821:virology; D012136:Respiratory Syncytial Viruses / Q000502:physiology
chemical_list: D000998:Antiviral Agents; D000069455:Palivizumab